Bypass surgery versus stents for people with weak heart pumping and blockages in multiple coronary arteries
Official title: Surgical Versus Percutaneous Revascularization in Patients With Reduced Left Ventricular Function
Run by University Medical Center Groningen · NCT07269366 · Data updated 2026-11-12
This trial tests whether bypass surgery (CABG) or stents (PCI) lead to better survival, fewer major heart problems, and improved quality of life for adults with reduced left ventricular function (LVEF ≤40%) and multivessel coronary disease.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 358 (estimated) |
| Sponsor | University Medical Center Groningen Academic / other |
| Locations | 1 site (Groningen) |
| Status | Recruiting |
| Started | May 2026 |
| Main results expected | May 2034 |
| Study ends | May 2034 |
| Registry record updated | May 12, 2026 |
| Trial ID | NCT07269366 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18 years) with ischemic LV systolic dysfunction (LVEF ≤40%), multivessel CAD, and recent angina or hospitalization for ACS or heart failure who are judged suitable for either CABG or PCI by the local Heart Team are ideal candidates.
✕Probably not a fit
Patients with ACS within 48 hours, prior CABG, valvular disease requiring intervention, contraindications to dual antiplatelet therapy, decompensated heart failure at enrollment, or noncardiac conditions with life expectancy under one year are unlikely to benefit from enrollment.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, randomized, open-label, multicenter trial enrolling 358 adults with ischemic left ventricular systolic dysfunction (LVEF ≤40%) and multivessel coronary artery disease. Participants are randomized 1:1 to undergo coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) with the aim of full revascularization. The primary endpoint is a hierarchical composite of all-cause mortality, recurrent major adverse cardiovascular events (non-procedural MI, stroke, unplanned revascularization), and recurrent heart failure hospitalizations over 4 years. Secondary outcomes include the individual components of the composite and quality-of-life measures, and the results will contribute to the international STICH 3.0 collaboration.
Why it matters
Potential benefit: If successful, the trial could show which revascularization approach gives better long-term survival, fewer major cardiac events, and improved quality of life for patients with low ejection fraction.
How similar studies have gone: Previous STICH trials showed CABG improves long-term survival compared with medical therapy in this population, but randomized comparisons between modern CABG and PCI for patients with low LVEF are limited, so this trial addresses a key evidence gap.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * LVEF≤ 40% * Angina pectoris, CCS≥2 and/or hospitalization for ACS or heart failure within 1 year prior to randomization * Multivessel CAD (2-3 vessel-disease with coronary lesions \>70% and involvement of proximal LAD, and/or LM stenosis of \>50%). Target vessels are determined by the local Heart Time * Clinical and angiographical characteristics suitable for isolated coronary revascularization both by CABG or PCI according to the judgment of the local Heart Team * Written informed consent Exclusion Criteria: * ACS \< 48 hours before randomization * Valvular/structural heart disease requiring intervention * Contra-indications to DAPT * Non-cardiac condition with life expectancy \< 1 year * Previous CABG * Decompensated HF at the time of inclusion
Where it's running
-
University Medical Center Groningen
Groningen, Netherlands Recruiting
Study contacts
- Principal investigator: Erik Lipsic, Dr — University Medical Center Groningen
- Study coordinator: Erik Lipsic, Dr
- Email: e.lipsic@umcg.nl
- Phone: +31 50 3612355
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AI-powered ECG to help diagnose and predict outcomes in heart disease
Researchers test an AI-enhanced ECG to help diagnose and predict outcomes for people with cardiovascular diseases.
-
SiroMax sirolimus-coated balloon for small coronary vessels with or without prior stents
A first-in-human test to see if the SiroMax drug-coated balloon can safely open narrow coronary arteries in adults with or without prior stents.
-
Impact of Procedural Factors on Drug-Coated Balloon Outcomes in Coronary Artery Disease
This registry tests whether delivery time and inflation duration of drug-coated balloons affect outcomes in adults undergoing PCI for new coronary lesions.
-
Low-dose IL-2 after heart attack to study tissue-resident regulatory T cells
Researchers are testing whether low-dose interleukin-2 given after a myocardial infarction can boost tissue-resident regulatory T cells to support heart repair.
-
Impact of a Clinical Information System on hospital outcomes for adults with chronic diseases
This study tests whether implementing a Clinical Information System helps reduce readmissions or death within 30 days after hospital discharge for adults with chronic conditions in Alberta.
-
Inspiron EVO stent in complex coronary lesions in Brazil
This study tests how well and safely the Inspiron EVO drug-eluting stent works in real-world patients with complex coronary artery disease in Brazil.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.